| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
In new data from Icosavax’s IVX-121 Phase 1b extension trial in older adults, GMTs against RSV through day 365 persisted at ~45-70% of the GMTs at day 28 (for 75 and 250 µg unadjuvanted dosages) -
- Data provide additional clinical evidence of potential differentiation on durability with company’s VLP platform technology -
- Robust immune response against RSV-A observed in Phase 1b extension trial participants who were revaccinated with IVX-121 twelve months following initial dose -
- IVX-121 continues to be generally well tolerated with no additional safety concerns observed with longer-term follow up or revaccination -
- IVX-A12 (a potential-first-in-class bivalent combination of IVX-121 for RSV and IVX-241 for hMPV) currently in a Phase 2 trial; Phase 2 topline interim data now expected by end 2023 -
Posted In: ICVX
